Under the Securities Exchange Act of 1934 (Amendment No. _____)* CYTOCLONAL PHARMACEUTICS INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 23282G105 (CUSIP Number) Andrea Kramer, c/o Roan Meyers Associates, L.P., 17 State Street, 19th Floor, New York, NY 10004 (212) 742-4200 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) April 28, 2000 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [] CUSIP No..... 23282G105 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Bruce Meyers SS####-##-#### 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) N/A (b) N/A 3. SEC Use Only 4. Source of Funds (See Instructions) PF (Long-term investment) 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) N/A 6. Citizenship or Place of Organization

.....

SCHEDULE 13D

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

May 11, 2000

.....

Bruce Meyers
Signature
Bruce Meyers
Name/Title

Date

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)